S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
This Stock Could Go Up 66% or More. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:INBX

Inhibrx (INBX) Stock Forecast, Price & News

$19.48
-0.04 (-0.20%)
(As of 09/22/2023 ET)
Compare
Today's Range
$18.79
$19.88
50-Day Range
$15.75
$25.38
52-Week Range
$12.94
$34.72
Volume
454,379 shs
Average Volume
539,492 shs
Market Capitalization
$850.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.33

Inhibrx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
127.6% Upside
$44.33 Price Target
Short Interest
Bearish
15.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
0.48mentions of Inhibrx in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$9.90 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.08) to ($4.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

193rd out of 965 stocks

Biological Products, Except Diagnostic Industry

26th out of 160 stocks


INBX stock logo

About Inhibrx (NASDAQ:INBX) Stock

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

INBX Price History

INBX Stock News Headlines

Inhibrx (NASDAQ:INBX) Stock Price Down 2.2%
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
LifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX)
Inhibrx: Undercovered Company With Good Potential
See More Headlines
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

INBX Company Calendar

Last Earnings
8/07/2023
Today
9/24/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.33
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+127.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-145,230,000.00
Net Margins
-28,749.25%
Pretax Margin
-28,748.58%

Debt

Sales & Book Value

Annual Sales
$2.19 million
Book Value
$1.33 per share

Miscellaneous

Free Float
33,974,000
Market Cap
$850.69 million
Optionable
Not Optionable
Beta
2.68
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Mark Paul LappeMr. Mark Paul Lappe (Age 56)
    Founder, Chairman, Pres & CEO
    Comp: $1.02M
  • Dr. Brendan P. Eckelman Ph.D. (Age 44)
    Founder & Chief Scientific Officer
    Comp: $704k
  • Ms. Kelly Devine Deck B.S. (Age 42)
    CPA, M.S., Exec. VP & CFO
    Comp: $531.17k
  • Mr. Quinn L. Deveraux
    Founder
  • Dr. Ashraf Amanullah (Age 55)
    Exec. VP & Chief Technical Operations Officer
  • Ms. Leah Pollema J.D.
    VP, Corp. Sec. & Gen. Counsel
  • Dr. Charbel Helaihel Pharm.D.
    VP of Marketing & Commercial Planning
  • Mr. Jeffrey J. JensenMr. Jeffrey J. Jensen
    Exec. VP & Chief Clinical Operations Officer
  • Mr. David Matly M.B.A.
    Exec. VP & Chief Commercial Officer
  • Dr. Carlos Bais Ph.D.
    Exec. VP of Translational Sciences













INBX Stock - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INBX shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price forecast for 2023?

4 brokerages have issued 12 month price targets for Inhibrx's shares. Their INBX share price forecasts range from $27.00 to $60.00. On average, they predict the company's stock price to reach $44.33 in the next twelve months. This suggests a possible upside of 127.6% from the stock's current price.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2023?

Inhibrx's stock was trading at $24.64 at the beginning of the year. Since then, INBX stock has decreased by 20.9% and is now trading at $19.48.
View the best growth stocks for 2023 here
.

Are investors shorting Inhibrx?

Inhibrx saw a decline in short interest in August. As of August 31st, there was short interest totaling 5,090,000 shares, a decline of 12.8% from the August 15th total of 5,840,000 shares. Based on an average trading volume of 398,300 shares, the days-to-cover ratio is presently 12.8 days. Approximately 15.3% of the shares of the stock are sold short.
View Inhibrx's Short Interest
.

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our INBX earnings forecast
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) released its quarterly earnings results on Monday, August, 7th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by $0.06. The company had revenue of $0.03 million for the quarter. Inhibrx had a negative net margin of 28,749.25% and a negative trailing twelve-month return on equity of 5,168.31%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Inhibrx's stock symbol?

Inhibrx trades on the NASDAQ under the ticker symbol "INBX."

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (8.30%), BlackRock Inc. (5.83%), State Street Corp (4.16%), Woodline Partners LP (3.49%), ArrowMark Colorado Holdings LLC (2.20%) and Geode Capital Management LLC (1.51%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends
.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibrx's stock price today?

One share of INBX stock can currently be purchased for approximately $19.48.

How much money does Inhibrx make?

Inhibrx (NASDAQ:INBX) has a market capitalization of $850.69 million and generates $2.19 million in revenue each year. The company earns $-145,230,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis.

How many employees does Inhibrx have?

The company employs 132 workers across the globe.

How can I contact Inhibrx?

Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The official website for the company is www.inhibrx.com. The company can be reached via phone at 858-795-4220 or via email at amy@juniper-point.com.

This page (NASDAQ:INBX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -